Nanotechnology-based approaches hold substantial potential for improving the care of
patients with diabetes. Nanoparticles are being developed as imaging contrast agents to …

Type 1 diabetes (T1D) is a chronic autoimmune disease in which destruction or damaging of
the beta-cells in the islets of Langerhans results in insulin deficiency and hyperglycemia. We …

Magnetic nanoparticles with appropriate surface coatings are increasingly being used
clinically for various biomedical applications, such as magnetic resonance imaging …

Clinical islet transplantation is gaining acceptance as a potential therapy, particularly for
subjects who have labile diabetes or problems with hypoglycemic awareness. The risks of …

The pathways that control insulin secretion and regulate pancreatic β-cell mass are crucial
in the development of diabetes mellitus. Maturity-onset diabetes of the young comprises a …

Aims/hypothesis A reliable method for in vivo quantification of pancreatic beta cell mass
(BCM) could lead to further insight into the pathophysiology of diabetes. The glucagon-like …

Type 1 diabetes mellitus is characterized by the selective destruction of insulin-producing
beta cells, which leads to a deficiency in insulin secretion and, as a result, to hyperglycemia …

Type 2 diabetes is increasingly viewed as a disease of insulin deficiency due not only to
intrinsic pancreatic β-cell dysfunction but also to reduction of β-cell mass. It is likely that, in …

The hallmark of type 1 diabetes is autoimmune destruction of the insulin-producing β-cells of
the pancreatic islets. Autoimmune diabetes has been difficult to study or treat because it is …

Diabetes results from an absolute or relative reduction in pancreatic β cell mass (BCM)
leading to insufficient insulin secretion and hyperglycemia. Measurement of insulin secretory …